Akebia Therapeutics (AKBA) said Tuesday it signed a commercial contract with a kidney care services provider to help expand access to Vafseo, or vadadustat, for patients on dialysis.
Vafseo is indicated to treat anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months, the company said.
Under the multiyear contract, physicians will be able to prescribe Vafseo to patients on dialysis as deemed clinically appropriate. Akebia said it expects Vafseo to be available in the US in January 2025.
The company's shares were up nearly 6% in recent trading.
Price: 1.45, Change: +0.08, Percent Change: +5.84
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。